Psoriatic arthritis treatment update

Bulletin of the NYU Hospital for Joint Diseases

Volumn 69, Issue 3, 2011, Pages 243-249

  Mease, Philip J ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ABCIXIMAB; ADALIMUMAB; ALEFACEPT; ANALGESIC AGENT; BIOLOGICAL RESPONSE MODIFIER; CD20 ANTIBODY; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 6; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ABLATION THERAPY; ACUTE KIDNEY FAILURE; ANKYLOSING SPONDYLITIS; ARTICLE; B LYMPHOCYTE; DRUG EFFICACY; HUMAN; HYPERTENSION; MONOTHERAPY; MUSCULOSKELETAL SYSTEM INFLAMMATION; NONALCOHOLIC FATTY LIVER; OSTEOARTHRITIS; PSORIASIS; PSORIATIC ARTHRITIS; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; DRUGS, INVESTIGATIONAL; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME;

EID: 80054091144     PISSN: 19369719     EISSN: 19369727     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Chandran V, Raychaudhuri SP. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun. 2010;34(3):J314-21.
2. Bakker MF, Jacobs JW, Verstappen SM, Bijlsma JW. Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility. Ann Rheum Dis. 2007;66 Suppl 3:iii56-60.
3. Mease PJ. Improving the routine management of rheumatoid arthritis: the value of tight control. J Rheumatol 2010;37:1570-8.
4. Mease P, Antoni C, Gladman DD, Taylor W. Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis 2005;64:ii49-54.
5. Mease P. Assessment of psoriatic arthritis. Arthritis Care Res. 2011;63:in press.
6. Helliwell PS, Fitzgerald O, Strand CV, Mease PJ. Composite measures in psoriatic arthritis: a report from the GRAPPA 2009 annual meeting. J Rheumatol. 2011;38:540-5.
7. Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis. 2010;69:48-53.
8. Coates LC, Cook R, Lee KA, et al. Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort. Arthritis Care Res. 2010;62:970-6.
9. Coates LC, Helliwell PS. Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res. 2010;62:965-9.
10. Ritchlin CT, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis. 2009;68:1387-94.
11. Kavanaugh AF, Ritchlin CT. Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines. J Rheumatol. 2006;33:1417-21.
12. Soriano ER, McHugh NJ. Therapies for peripheral joint disease in psoriatic arthritis. A systematic review. J Rheumatol. 2006;33:1422-30.
13. Nash P. Therapies for axial disease in psoriatic arthritis. A systematic review. J Rheumatol. 2006;33:1431-4.
14. Ritchlin CT. Therapies for psoriatic enthesopathy. J Rheumatol. 2006;33:1435-8.
15. Helliwell PS. Therapies for dactylitis in psoriatic arthritis. A systematic review. J Rheumatol. 2006;33:1439-41.
16. Strober BE, Siu K, Menon K. Conventional systemic agents for psoriasis. J Rheumatol. 2006;33:1442-6.
17. Boehncke WH, Prinz J, Gottlieb AB. Biologic therapies for psoriasis. A systematic review. J Rheumatol. 2006;33:1447-51.
18. Cassell S, Kavanaugh AF. Therapies for psoriatic nail disease. J Rheumatol. 2006;33:1452-6.
19. Nash P, Clegg DO. Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Ann Rheum Dis. 2005;64:ii74-7.
20. Mease PJ. Psoriatic arthritis: update on pathophysiology, assessment and management. Ann Rheum Dis. 2011; 70 Suppl 1:i77-84.
21. Kingsley GH, Kowalczyk A, Taylor H, et al. Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial. Arthritis Rheum. 2010;62:S277.
22. Abu-Shakra M, Gladman DD, Thorne JC, et al. Long-term methotrexate therapy in psoriatic arthritis: clinical and radiological outcome. J Rheumatol. 1995;22:241-5.
23. Whiting-O'Keefe QE, Fye KH, Sack KD. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med. 1991;90:711-6.
24. Kalb RE, Strober B, Weinstein G, Lebwohl M. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol. 2009;60:824-37.
25. Raffayova H, Kungurov N, Baranauskaite A, et al. Infliximab plus methotrexate significantly improves rates of remission for methotrexate naive psoriatic arthritis (PsA) patients compared to methotrexate alone: The RESPOND trial. Arthritis Rheum. 2009;60:S470-1.
26. Karanikolas GN, Arida K, Komninou E, et al. Combination of adalimamab with cyclosporine-a against single therapy in refractory psoriatic arthritis: An interim analysis of an ongoing, 12-month open, three-arm, randomized trial. Ann Rheum Dis. 2009;68:138-9.
27. Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004;50:2264-72.
28. Mease PJ, Kivitz AJ, Burch FX, et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol. 2006;33:712-21.
29. Sterry W, Ortonne JP, Kirkham B, et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ. 2010;340:c147.
30. Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005;64:1150-7.
31. Mease P, Gladman D, Ritchlin C. Adalimumab in the treatment of patients with moderately to severely active psoriatic arthritis: Results of ADEPT. Arthritis Rheum. 2005;58:3279-89.
32. Mease PJ, Ory P, Sharp JT, et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis. 2009;68:702-9.
33. Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 2009;60:976-86.
34. Kavanaugh A, Mease P, Krueger GG, et al. Golimumab, a new, human, TNF alpha antibody, administered subcutaneously every 4 weeks in psoriatic arthritis patients: 104-week efficacy and safety results of the randomized, placebo-controlled GOREVEAL study. Ann Rheum Dis. 2009;68:136-7.
35. Kavanaugh A, van der H.D, Gladman D, et al. Golimumab inhibits progression of radiographic damage in patients with psoriatic arthritis: 52 week results from the GO-REVEAL study [abstract]. Ann Rheum Dis. 2010;69:116.
36. Van den Bosch F, Manger B, Goupille P, et al. Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions. Ann Rheum Dis. 2010;69:394-9.
37. Zochling J, van der Heijde D, Dougados M, Braun J. Current evidence for the management of ankylosing spondylitis a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis. 2006;65(4):423-32.
38. Mease PJ, Gladman DD, Keystone EC. Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2006;54:1638-45.
39. Mease PJ, Reich K. Alefacept with methotrexate for treatment of psoriatic arthritis: open-label extension of a randomized, double-blind, placebo-controlled study. J Am Acad Dermatol. 2009;60:402-11.
40. Abrams JR, Lebwohl M, Guzzo C. CTLA4Ig-mediated blockade of T cell co-stimulation in patients with psoriasis vulgaris. J Clin Invest. 1999;103:1243-52.
41. Mease P, Genovese MC, Gladstein G, et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebocontrolled, phase II trial. Arthritis Rheum. 2011;63(4):939-48.
42. Leipe J, Grunke M, Dechant C, et al. Role of Th17 cells in human autoimmune arthritis. Arthritis Rheum. 2010;62(10):2876-85.
43. Krueger GG, Langley RG, Leonardi C, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med. 2007;356:580-92.
44. Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet. 2009;373:633-40.
45. Mease P, Genovese M, Ritchlin C, et al. Rituximab in psoriatic arthritis: results of an open label study Ann Rheum Dis. 2010;69:116.
46. Hueber W, Patel DD, Dryja T, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med. 2010; 2(52):52-72.
47. Baeten D, Sieper J, Emery P, et al. The anti-IL17A monoclonal antibody secukinumab (AIN457) showed good safety and efficacy in the treatment of active ankylosing spondylitis. Ann Rheum Dis. 2011;70:127.
48. Papp K, et al. Presented at the World Congress of Dermatology, Seoul, Korea, 2011
49. Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008;58:851-64.